Fosun International's 2024 Results: A Powerhouse Performance!
Generado por agente de IAWesley Park
domingo, 30 de marzo de 2025, 10:06 am ET2 min de lectura
Ladies and gentlemen, buckle up! We've got a powerhouse performance to talk about today. Fosun International just dropped its 2024 annual results, and let me tell you, this is a company that's not just weathering the storm—it's thriving in it! Total revenue hit a staggering RMB192.14 billion, and industrial operation profit amounted to RMB4.9 billion. This is not just stability; this is a rocketRCKT-- ship to the moon!

Let's break it down, folks. Fosun's four core subsidiaries—Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group—generated a whopping RMB134.65 billion, accounting for 70.1% of the Group's total revenue. That's right, 70.1%! These guys are the backbone of Fosun's success, and they're showing no signs of slowing down.
Now, let's talk about that industrial operation profit. RMB4.9 billion is nothing to sneeze at, especially in today's market. But here's the kicker: the Group's loss attributable to owners of the parent amounted to RMB4.35 billion, mainly due to a one-off non-cash loss. Excluding this, the profit attributable to owners of the parent amounted to RMB0.75 billion. That's right, folks, the underlying operations are rock solid!
Fosun's operating cash flow remained healthy and stable, with a total debt to total capital ratio of 52%. They've been optimizing their asset portfolio like crazy, with signed asset divestment amounting to approximately RMB17.5 billion equivalent at the group level, and approximately RMB30.0 billion equivalent at the consolidated level. This is not just about cutting costs; this is about building a fortress against external risks and seizing investment opportunities.
And get this, folks: in November 2024, after an absence of three years, Fosun returned to the offshore USD bond market and successfully issued long duration USD bonds. They refinanced their three-year unsecured syndicated loan with upsize from matured loan, achieving the successful launch of offshore syndicated loans for 8 consecutive years. Fosun High Technology issued several super short-term commercial papers, raising a total of RMB5.1 billion. In June 2024, the international credit rating agency S&P fully recognized the Group's steady improvement in credit matrix, and reaffirmed the BB- rating and a stable credit outlook. This is not just about financial stability; this is about dominance!
But wait, there's more! Fosun's overseas revenue grew 6.2% year-on-year, increasing the proportion of overseas revenue to 49.3% of total revenue. This is not just about globalization; this is about conquering the world! For example, Henlius, one of Fosun's subsidiaries, achieved overseas sales revenues of RMB121 million, marking a 30.76% increase year-on-year. HANSIZHUANG was approved for marketing in the European Union; HANQUYOU was approved for marketing in the U.S. and Canada, embarking on a new journey of commercialization in North America; HANLIKANG, the first biosimilar in China, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG. This is not just about innovation; this is about world domination!
And let's not forget about technology innovation. Fosun's investment in technology innovation reached approximately RMB6.9 billion during the reporting period, highlighting its emphasis on continuous improvement and modernization across its business sectors. The Group established over 20 global innovation centers aimed at fostering R&D efforts, particularly in pharmaceuticals where they saw a series of product approvals over the year. This is not just about staying ahead of the curve; this is about setting the curve!
So, what's the bottom line, folks? Fosun International is a powerhouse, and its 2024 annual results are a testament to that. This is a company that's not just surviving; it's thriving. This is a company that's not just innovating; it's dominating. This is a company that's not just globalizing; it's conquering the world. So, do yourself a favor and get in on the action. Fosun International is the next big thing, and you don't want to miss out on this rocket ship to the moon!
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios